Clearview Chlamydia (Unipath) is a rapid monoclonal antibody based latex immunodiffusion test for detecting chlamydial antigen in endocervical specimens. The assay does not require specialised equipment or extensive training and takes less than 30 minutes from sample to results. The clinical performance of Clearview Chlamydia was evaluated with 478 paired endocervical swabs from patients attending a genitourinary medicine clinic. In the first part of the study, 221 non-randomised specimens were tested by cell culture (lst swab) and Clearview (2nd swab) whereas in the second part of the study 257 randomised swabs were examined by Clearview, cell culture and immunofluorescence. Theoverallprevalenceof chlamydial infection was 8-8% and the sensitivity, specificity, positive and negative predictive values for Clearview were 85-7%, 99-1%, 90% and 98-6%. The test requires further evaluation to establish its role in the management and control of chlamydial infection.
Introduction
Infection with Chlamydia trachomatis is probably the most common sexually transmitted disease in the western world.' In the case ofmen, presentation with a non-gonococcal urethritis (NGU) with urethral discharge will lead to the prescription of an appropriate effective antibiotic, whereas diagnosis in women on the grounds of clinical signs is quite unreliable and appropriate therapy will often not be given. Whilst the majority of infections in women may be asymptomatic, infection with C trachomatis is capable of inducing a plasma cell endometritis, salpingitis and peritonitis with associated Clearview Chlamydia Immediately after the smear had been prepared the swab was replaced in its sleeve (no transport medium) and transported to the laboratory within three hours. If the Clearview test was not performed the same day, swabs were stored at 4'C and tested within three days according to the manufacturer's instructions. The swab was placed in a small flexible plastic extraction tube containing 0-6 ml extraction buffer and agitated. The extraction tube containing the swab was then placed in a heating block at 80°C for ten minutes. On removing the extraction tube from the heating block the swab was rotated in the buffer and removed from the tube: liquid was thoroughly removed from the swab by pinching the rim of the extraction tube between thumb and forefinger and squeezing the swab as it was removed from the tube. After cooling for five minutes at room temperature a drop of antibody coated latex suspension (blue latex particles coated with genus specific monoclonal antibody against chlamydial lipopolysaccharide) was added and mixed with the extract. The extraction tube was then capped with an integral cap which has an in-built filter and acts as a dropper for applying sample to the test device. Five drops of this mixture were then added to an absorbent pad in the sample window of a small (8-5 cm x 3-0 cm) immunochromatographic device. The mixture migrates from the sample window along a strip to the "Result Window": the formation of a blue line in the result window (within 5 minutes) indicates the presence of chlamydial antigen in the extract. The line is formed due to however, found the sensitivity of IDEIA (96-3%) was higher than that of Chlamydiazyme (85-2%). The IDEIA III version of the assay which used Fab fragments rather than whole monoclonal immunoglobulin G as the capture antibody yielded sensitivity, specificity, positive and negative predictive values of 93-8%, 99%, 92-9% and 99-1% respectively."
Processing of samples by the above non-cultural assays takes several hours and although they are ideally suited to batch testing in the laboratory they cannot be used as an "on-the-spot" test when the patient is at the clinic. The new rapid tests which are available yield similar results to the above EIAs but can be performed at the time of the patient's visit. TestPack Chlamydia (Abbott Laboratories) is a direct EIA for the detection of chlamydial antigen in endocervical specimens.'5 The assay requires no specialised equipment and yields results in less than 30 minutes. When the assay was evaluated against cell culture and/or chlamydial antigen positive (confirmed Chlamydiazyme or IF staining) in a population with a prevalence of chlamydial infection of 13-8% the assay yielded a sensitivity, specificity, positive and negative predictive values of 76-5%, 99-5%, 96-2% and 96-5% respectively.'5 In our study Clearview Chlamydia gave a slightly higher sensitivity (85-7%) in a population with a lower prevalence (8-8%) of chlamydial infection. The various factors that must be taken into account when selecting tests for chlamydial infection are discussed in detail by Barnes.4 The development of these new tests, however, means that the advantages of rapid antigen detection thus enabling the patient to receive immediate effective treatment require greater consideration. The use of these immediate tests must be deliberated against the setting where epidemiological treatment is widely practised.' Within Genitourinary medicine clinics epidemiological treatment is usually given to women who are known contacts of men with NGU. In this context it is interesting that 40% (8/20) of the Clearview positive patients were not known contacts of men with NGU and would not have been treated on epidemiological grounds. In contrast, 10-3% (24/232) of the chlamydia negative patients were contacts of men with NGU and would have received epidemiological treatment. Despite epidemiological treatment the knowledge of whether a patient is chlamydia positive or negative may be useful, particularly when there is a risk to other contacts.
Because culture following storage at -70°C may result in a slightly decreased sensitivity it is possible that we have over-estimated the sensitivity of Clearview. Nevertheless 
